AMENDMENTS TO THE CLAIMS

Please delete all prior lists of claims in the application and insert the following list of claims:

1-4 (CANCELED).

5. (CURRENTLY AMENDED) A compound of structural formula (I) for use as an activator of histone acetyltransferases:



(I)

wherein:

R^1 is selected from the group consisting of ~~hydrogen~~, ~~C_1~~ C_2- to C_{16}-alkyl and ~~C_1~~ C_2- to C_{16}-alkene;

R^2 is selected from the group consisting of hydrogen, and C_1- to C_6-alkyl;

R^3 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, I, and CN;

R^4 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, I, and CN;

R^5 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3,

F, Cl, I, and;

R^6 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, CI_3, F, Cl, I, and CN;

R^7 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, CI_3, F, Cl, I, and CN; and

R^8, R^9, and R^{10} are independently selected from the group consisting of hydrogen, C_1- to C_{16}-alkyl, C_1- to C_{16}-alkene, and C_1- to C_{16}-alkoxy;

and salts thereof.

6. (CURRENTLY AMENDED) The compound of claim 5, wherein:

R^1 is selected from the group consisting of ~~methyl, ethyl,~~ n-propyl, isopropyl, n-butyl, t-butyl, C_8H_{18}, $C_{15}H_{26}$, $C_{15}H_{28}$, $C_{15}H_{30}$, and $C_{15}H_{32}$;

R^2 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl;

R^3 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF_3, CCl_3, CI_3, F, Cl, I, and CN;

R^4 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF_3, CCl_3, CI_3, F, Cl, I, and CN;

R^5 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF_3, CCl_3, CI_3, F, Cl, and I;

R^6 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF_3, CCl_3, CI_3, F, Cl, I, and CN; and

R^7 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF_3, CCl_3, CI_3, F, Cl, I, and CN.

7. (PREVIOUSLY PRESENTED) A compound selected from the group consisting of:

N-(4-nitro-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide;

N-(4-nitro-3-trifluoromethyl-phenyl)-2-propoxy-benzamide;

N-(4-nitro-3-trifluoromethyl -phenyl)-2-isopropoxy-benzamide;

N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;

N-(4-cyano-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;

N-(4-chloro-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;

N-(4-cyano-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;

N-(4-chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-6-pentadecyl-benzamide;

N-(4-chloro-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;

N-(4-cyano-3-trifluoromethyl-phenyl)-2-n-propoxy-6-pentadecyl-benzamide;

N-(4-cyano-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;

N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide;

N-(4-cyano-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide;

N-(4-chloro-3-trifluoromethyl-phenyl)-2-methoxy-benzamide;

N-(4-cyano-3-trifluoromethyl-phenyl)-2-methoxy-benzamide;

N-(4-chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide;

N-(4-cyano-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide;

N-(4-nitro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;

N-(4-nitro-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;

N-(4-fluoro-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;

N-(4-fluoro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;

N-(4-fluoro-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;

N-(4-fluoro-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;

N-(4-iodo-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;

N-(4-iodo-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;

N-(4-iodo-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;

N-(4-iodo-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;

N-(4-bromo-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;

N-(4-bromo-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;
N-(4-bromo-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;
N-(4-bromo-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;
N-(4-carboxylic-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;
N-(4- carboxylic -3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;
N-(4- carboxylic -3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;
N-(4- carboxylic-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;
N-(4-nitro-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide; and
N-(4-nitro-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;
and salts thereof.

8. (CURRENTLY AMENDED) A compound of structural formula (I):



(I)

wherein R^1, is selected from the group consisting of C_{14}- to C_{16}-alkyl and C_{14}- to C_{16}-alkenyl ~~R2, R8, R9 and R10 are defined such that the ring moiety to which R1, R2, R8, R9 and R10 are attached defines a moiety selected from the group consisting of anacardic acid, anacardic aldehyde, anacardic alcohol, 2-ethoxy-6-pentadecyl-benzoic acid, cardanol, and cardol~~;

R_2 is selected from the group consisting of hydrogen, methyl, and ethyl;

R^3 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, I, and CN;

R^4 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, I, and CN;

R^5 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, and I;

R^6 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, I, and CN; ~~and~~

R^7 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, I, and CN;

R^8 and R^{10} are hydrogen; and

R^9 is selected from the group consisting of hydrogen and hydroxy;

and salts thereof.

9. (CURRENTLY AMENDED) A compound of structural formula (I):



(I)

wherein R^1 is selected from the group consisting of C_{12}- to C_{16}-alkyl and C_{12}- to C_{16}-

alkene~~, and R2, R8, R9 and R10 are hydrogen~~:

R^2 is selected from the group consisting of hydrogen, and C_1- to C_6-alkyl;

R^3 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, I, and CN;

R^4 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, I, and CN;

R^5 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, and I;

R^6 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, I, and CN;

R^7 is selected from the group consisting of hydrogen, C_1- to C_6-alkyl, CF_3, CCl_3, Cl_3, F, Cl, I, and CN; and

R^8, R^9, and R^{10} are independently selected from the group consisting of hydrogen, C_1- to C_{16}-alkyl, C_1- to C_{16}-alkene, and C_1- to C_{16}-alkoxy;

and salts thereof.

10. - 13. (CANCELED)

14. (PREVIOUSLY PRESENTED) A pharmaceutical composition for treating cancer, acquired immune deficiency syndrome (AIDS), HIV infection, and asthma, the composition comprising an anti-cancer-, anti-AIDS-, anti-HIV- or anti-asthma-effective amount of a compound of claim 5 or a pharmaceutically suitable salt thereof, in combination with a pharmaceutically suitable carrier.

15. (CANCELED)

16. (CANCELED)